Skip to main content

Liver Transplantation for Cholangiocarcinoma

  • Chapter
  • First Online:
Diagnosis and Management of Cholangiocarcinoma

Abstract

Liver transplantation (LT) has been the gold standard treatment for patients with unresectable hepatocellular carcinoma for nearly three decades. More recently, a new era of “transplant oncology” has been ushered in with the recognition that LT is also a viable curative therapy for patients with cholangiocarcinoma (CCA). Initial success of LT for CCA was outlined by the Mayo Clinic experience for patients with unresectable hilar CCA (hCCA) measuring <3 cm managed on a strict pre-transplant protocol including neoadjuvant chemoradiotherapy and staging laparotomy to exclude lymph node metastases. More recently, numerous single-center and multicenter studies have identified excellent outcomes following LT for intrahepatic cholangiocarcinoma (iCCA) as well. While appropriateness of LT for patients with resectable hCCA or larger iCCA is debated, it’s increasingly clear that multimodal neoadjuvant therapy and appropriate patient selection are of paramount importance. Given the relative scarcity of available donor liver allografts, rigorous patient selection must be applied to mitigate oncologic risk and ensure meaningful organ utilization.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

CCA:

Cholangiocarcinoma

ERCP:

Endoscopic retrograde cholangiopancreatography

hCCA:

Hilar cholangiocarcinoma

iCCA:

Intrahepatic cholangiocarcinoma

LT:

Liver transplantation

MELD:

Model for end-stage liver disease

PSC:

Primary sclerosing cholangitis

References

  1. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224(4):463–73; discussion 73–5.

    Google Scholar 

  2. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234(4):507–17; discussion 17–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Nagino M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg. 2013;258(1):129–40.

    Article  PubMed  Google Scholar 

  4. Vilana R, Forner A, Bianchi L, Garcia-Criado A, Rimola J, de Lope CR, et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology. 2010;51(6):2020–9.

    Article  PubMed  Google Scholar 

  5. Ortner ME, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology. 2003;125(5):1355–63.

    Article  PubMed  Google Scholar 

  6. Verderame F, Russo A, Di Leo R, Badalamenti G, Santangelo D, Cicero G, et al. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. Ann Oncol. 2006;17(Suppl 7):vii68–72.

    Google Scholar 

  7. Grendar J, Grendarova P, Sinha R, Dixon E. Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: a systematic review. HPB (Oxford). 2014;16(4):297–303.

    Article  Google Scholar 

  8. Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796–807.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261–80.

    Article  PubMed  Google Scholar 

  10. Eckel F, Schmid RM. Emerging drugs for biliary cancer. Expert Opin Emerg Drugs. 2007;12(4):571–89.

    Article  CAS  PubMed  Google Scholar 

  11. Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):353–63.

    Article  CAS  PubMed  Google Scholar 

  12. Iwatsuki S, Todo S, Marsh JW, Madariaga JR, Lee RG, Dvorchik I, et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg. 1998;187(4):358–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Jonas S, Kling N, Guckelberger O, Keck H, Bechstein WO, Neuhaus P. Orthotopic liver transplantation after extended bile duct resection as treatment of hilar cholangiocarcinoma. First long-terms results. Transpl Int. 1998;11(Suppl 1):S206–8.

    Article  PubMed  Google Scholar 

  14. Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B Jr, McCashland T, et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant. 2002;2(8):774–9.

    Article  PubMed  Google Scholar 

  15. Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Nyberg SL, Ishitani MB, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis. 2004;24(2):201–7.

    Article  PubMed  Google Scholar 

  16. De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl. 2000;6(3):309–16.

    Article  PubMed  Google Scholar 

  17. Rosen CB, Darwish Murad S, Heimbach JK, Nyberg SL, Nagorney DM, Gores GJ. Neoadjuvant therapy and liver transplantation for hilar cholangiocarcinoma: is pretreatment pathological confirmation of diagnosis necessary? J Am Coll Surg. 2012;215(1):31–8; discussion 8–40.

    Article  PubMed  Google Scholar 

  18. Kipp BR, Stadheim LM, Halling SA, Pochron NL, Harmsen S, Nagorney DM, et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol. 2004;99(9):1675–81.

    Article  PubMed  Google Scholar 

  19. Duignan S, Maguire D, Ravichand CS, Geoghegan J, Hoti E, Fennelly D, et al. Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience. HPB (Oxford). 2014;16(1):91–8.

    Article  Google Scholar 

  20. Mantel HT, Westerkamp AC, Adam R, Bennet WF, Seehofer D, Settmacher U, et al. Strict selection alone of patients undergoing liver transplantation for hilar cholangiocarcinoma is associated with improved survival. PLoS One. 2016;11(6):e0156127.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Schule S, Altendorf-Hofmann A, Utess F, Rauchfuss F, Freesmeyer M, Knosel T, et al. Liver transplantation for hilar cholangiocarcinoma--a single-centre experience. Langenbeck's Arch Surg. 2013;398(1):71–7.

    Article  Google Scholar 

  22. Croome KP, Rosen CB, Heimbach JK, Nagorney DM. Is liver transplantation appropriate for patients with potentially resectable de novo hilar cholangiocarcinoma? J Am Coll Surg. 2015;221(1):130–9.

    Article  PubMed  Google Scholar 

  23. Ethun CG, Lopez-Aguiar AG, Anderson DJ, Adams AB, Fields RC, Doyle MB, et al. Transplantation versus resection for hilar cholangiocarcinoma: an argument for shifting treatment paradigms for resectable disease. Ann Surg. 2018;267(5):797–805.

    Article  PubMed  Google Scholar 

  24. Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005;242(3):451–8; discussion 8–61.

    Google Scholar 

  25. Matsuo K, Rocha FG, Ito K, D'Angelica MI, Allen PJ, Fong Y, et al. The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg. 2012;215(3):343–55.

    Article  PubMed  Google Scholar 

  26. Ziogas IA, Hickman LA, Matsuoka LK, Izzy M, Montenovo MI, Rega SA, et al. Comparison of wait-list mortality between cholangiocarcinoma and hepatocellular carcinoma liver transplant candidates. Liver Transpl. 2020;26:1112–20.

    Article  PubMed  Google Scholar 

  27. Sano T, Shimada K, Sakamoto Y, Yamamoto J, Yamasaki S, Kosuge T. One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality. Ann Surg. 2006;244(2):240–7.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, et al. Reply to: “Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma”. J Hepatol. 2019;71(6):1262–3.

    Article  PubMed  Google Scholar 

  29. Petrick JL, Thistle JE, Zeleniuch-Jacquotte A, Zhang X, Wactawski-Wende J, Van Dyke AL, et al. Body mass index, diabetes and intrahepatic cholangiocarcinoma risk: the liver cancer pooling project and meta-analysis. Am J Gastroenterol. 2018;113(10):1494–505.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Sapisochin G, Javle M, Lerut J, Ohtsuka M, Ghobrial M, Hibi T, et al. Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma: working group report from the ILTS transplant oncology consensus conference. Transplantation. 2020;104(6):1125–30.

    Article  PubMed  Google Scholar 

  31. Goldstein RM, Stone M, Tillery GW, Senzer N, Levy M, Husberg BS, et al. Is liver transplantation indicated for cholangiocarcinoma? Am J Surg. 1993;166(6):768–71; discussion 71–2.

    Google Scholar 

  32. O’Grady JG, Polson RJ, Rolles K, Calne RY, Williams R. Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg. 1988;207(4):373–9.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Robles R, Figueras J, Turrion VS, Margarit C, Moya A, Varo E, et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg. 2004;239(2):265–71.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, et al. Liver transplantation for “very early” intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment. Hepatology. 2016;64(4):1178–88.

    Article  CAS  PubMed  Google Scholar 

  35. Hong JC, Jones CM, Duffy JP, Petrowsky H, Farmer DG, French S, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg. 2011;146(6):683–9.

    Article  PubMed  Google Scholar 

  36. De Martin E, Rayar M, Golse N, Dupeux M, Gelli M, Gnemmi V, et al. Analysis of liver resection versus liver transplantation on outcome of small intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis. Liver Transpl. 2020;26(6):785–98.

    Article  PubMed  Google Scholar 

  37. Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N, et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol. 2018;3(5):337–48.

    Article  PubMed  Google Scholar 

  38. Flickinger JC, Epstein AH, Iwatsuki S, Carr BI, Starzl TE. Radiation therapy for primary carcinoma of the extrahepatic biliary system. An analysis of 63 cases. Cancer. 1991;68(2):289–94.

    Article  CAS  PubMed  Google Scholar 

  39. Akgul O, Bagante F, Olsen G, Cloyd JM, Weiss M, Merath K, et al. Preoperative prognostic nutritional index predicts survival of patients with intrahepatic cholangiocarcinoma after curative resection. J Surg Oncol. 2018;118(3):422–30.

    PubMed  Google Scholar 

  40. Sanchez AJ, Aranda-Michel J. Nutrition for the liver transplant patient. Liver Transpl. 2006;12(9):1310–6.

    Article  PubMed  Google Scholar 

  41. Isayama H, Komatsu Y, Tsujino T, Sasahira N, Hirano K, Toda N, et al. A prospective randomised study of "covered" versus “uncovered” diamond stents for the management of distal malignant biliary obstruction. Gut. 2004;53(5):729–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Jang S, Stevens T, Parsi M, Lopez R, Zuccaro G, Dumot J, et al. Association of covered metallic stents with cholecystitis and stent migration in malignant biliary stricture. Gastrointest Endosc. 2018;87(4):1061–70.

    Article  PubMed  Google Scholar 

  43. ASGE Standards of Practice Committee, Khashab MA, Chithadi KV, Acosta RD, Bruining DH, Chandrasekhara V, et al. Antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc. 2015;81(1):81–9.

    Article  Google Scholar 

  44. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168–79. https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(13)61903-0.pdf.

  45. Butler JR, Rogers T, Eckart G, Martens GR, Ceppa EP, House MG, et al. Is antisecretory therapy after pancreatoduodenectomy necessary? Meta-analysis and contemporary practices of pancreatic surgeons. J Gastrointest Surg. 2015;19(4):604–12.

    Article  PubMed  Google Scholar 

  46. Kaiser GM, Sotiropoulos GC, Jauch KW, Lohe F, Hirner A, Kalff JC, et al. Liver transplantation for hilar cholangiocarcinoma: a German survey. Transplant Proc. 2008;40(9):3191–3.

    Article  CAS  PubMed  Google Scholar 

  47. Rosen CB, Heimbach JK, Gores GJ. Surgery for cholangiocarcinoma: the role of liver transplantation. HPB (Oxford). 2008;10(3):186–9.

    Article  CAS  Google Scholar 

  48. Welling TH, Feng M, Wan S, Hwang SY, Volk ML, Lawrence TS, et al. Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma. Liver Transpl. 2014;20(1):81–8.

    Article  PubMed  Google Scholar 

  49. Zaborowski A, Heneghan HM, Fiore B, Stafford A, Gallagher T, Geoghegan J, et al. Neoadjuvant chemoradiotherapy and liver transplantation for unresectable hilar cholangiocarcinoma: the Irish experience of the Mayo protocol. Transplantation. 2020;104:2097–104.

    Article  CAS  PubMed  Google Scholar 

  50. Shimoda M, Farmer DG, Colquhoun SD, Rosove M, Ghobrial RM, Yersiz H, et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl. 2001;7(12):1023–33.

    Article  CAS  PubMed  Google Scholar 

  51. Sotiropoulos GC, Kaiser GM, Lang H, Molmenti EP, Beckebaum S, Fouzas I, et al. Liver transplantation as a primary indication for intrahepatic cholangiocarcinoma: a single-center experience. Transplant Proc. 2008;40(9):3194–5.

    Article  CAS  PubMed  Google Scholar 

  52. Vallin M, Sturm N, Lamblin G, Guillaud O, Hilleret MN, Hervieu V, et al. Unrecognized intrahepatic cholangiocarcinoma: an analysis of 993 adult cirrhotic liver explants. Clin Transpl. 2013;27(3):403–9.

    Article  Google Scholar 

  53. Sapisochin G, Rodriguez de Lope C, Gastaca M, Ortiz de Urbina J, Suarez MA, Santoyo J, et al. “Very early” intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients? Am J Transplant. 2014;14(3):660–7.

    Article  CAS  PubMed  Google Scholar 

  54. Facciuto ME, Singh MK, Lubezky N, Selim MA, Robinson D, Kim-Schluger L, et al. Tumors with intrahepatic bile duct differentiation in cirrhosis: implications on outcomes after liver transplantation. Transplantation. 2015;99(1):151–7.

    Article  PubMed  Google Scholar 

  55. Vilchez V, Shah MB, Daily MF, Pena L, Tzeng CW, Davenport D, et al. Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database. HPB (Oxford). 2016;18(1):29–34.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Vatche G. Agopian .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Butler, J.R., Agopian, V.G. (2021). Liver Transplantation for Cholangiocarcinoma. In: Tabibian, J.H. (eds) Diagnosis and Management of Cholangiocarcinoma. Springer, Cham. https://doi.org/10.1007/978-3-030-70936-5_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-70936-5_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-70935-8

  • Online ISBN: 978-3-030-70936-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics